相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS' COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 CONSENSUS STATEMENT - EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2013)
Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011 Impact of the Introduction of Dipeptidyl Peptidase-4 Inhibitors
Takahide Kohro et al.
INTERNATIONAL HEART JOURNAL (2013)
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians
Yoon Shin Cho et al.
NATURE GENETICS (2012)
Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients
Hiromi Iwahashi et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial
W. Yang et al.
DIABETES OBESITY & METABOLISM (2011)
Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
Jonatan I. Bagger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
Kohei Kaku et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
Nobuya Inagaki et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
Y. Seino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich Werner et al.
REGULATORY PEPTIDES (2010)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
Yan Gao et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Diabetes in Japan: a review of disease burden and approaches to treatment
Susan E. Neville et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2009)
Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
Takashi Kadowaki et al.
ENDOCRINE JOURNAL (2009)
Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia A nested case-control analysis
Michael Bodmer et al.
DIABETES CARE (2008)
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
Y. Seino et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus
Kazuki Yasuda et al.
NATURE GENETICS (2008)
Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes
M Fukushima et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population
C Saloranta et al.
DIABETES CARE (2002)
β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US
CC Jensen et al.
DIABETES (2002)
分享论文
